Mera-med.ru

Онкология
- Лечение онкологии
- Меланома
- Лейкоз
- Острый лейкоз
- Хронический лейкоз
- Лейкоз крови
- Рак



















консультация с онкологом в москве

Unresolved there is a question on optimum duration of chemotherapy of the first line. Today it is possible to recommend an individual approach in each concrete case. At a stage of chemotherapy of the first line it is necessary to aspire to achievement of full regress with disappearance of all displays of illness including normalization of level СА-125, and then to fix the achieved effect carrying out of 2-3 more additional rates. At achievement of partial regress it is necessary to continue chemotherapy till the moment when during two last rates stabilization of illness is marked, estimating on the sizes of residual tumoral weights and concentration of tumoral markers. By own experience I can tell, that in these cases at the majority of patients the number of courses of treatment will make from 6 up to 12, but not less than 6. In case of stabilization of illness it is necessary to limit volume of treatment by 6 rates after which end therapy can be stopped up to attributes of progressing or it is continued with use of modes of the second line depending on the general{common} condition of the patient and its{her} attitude{relation} to the further carrying out chemotherapy. At progressing illness it is necessary to pass to modes of the second line of chemotherapy. Подробнее...

The data of the first intermediate analysis of results of research BCRIG01 are published, in which comparison of efficiency of standard mode FAC (500/50/500) with a таксан-containing mode (with inclusion Таксотера) ТАС (75/50/500 (1) is lead{carried out}. Both modes were used with an interval of 3 weeks in quantity{amount} of 6 rates. This first published research estimating a role доцетаксела (Таксотера) in адъювантной of therapy of a cancer dairy железы. Earlier in two other researches (С9344 and В30) the role паклитаксела has been investigated, and one of them (С9344) has shown increase безрецидивной and the general{common} survival rate at patients with рецептороотрицательными tumours at use паклитаксела is consecutive with a mode the EXPERT. Подробнее...